EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

High-Dose Carbon Ion Reirradiation for Recurrent Pelvic Sarcomas: A Retrospective Analysis of Oncologic Outcomes in a Referral Center

Agnieszka Chalaszczyk, Elettra Dorotea Ferrari, Marco Rotondi, Silvia Molinelli, Amelia Barcellini, Viviana Vitolo, Giulia Fontana, Sara Scardo, Giuseppe Magro, Alessia Bazani, Mario Ciocca, Ester Orlandi und 1 weitere

Advances in Radiation Oncology · 2026-11 · 11 (11) · 102137

DOI: 10.1016/j.adro.2026.102137 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advances in Radiation Oncology, 2026-11. Verfasst von Agnieszka Chalaszczyk und 12 weiteren Autor:innen. Beteiligte Einrichtung: Radiation Oncology Unit, Clinical Department, CNAO National Center for Oncological Hadrontherapy, Pavia, Italy. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

This study aims to evaluate the safety and efficacy of high-dose carbon ion reirradiation (CIR) in patients with recurrent pelvic sarcomas. Methods and Materials: This retrospective study included 46 patients treated with high-dose CIR for locoregional recurrences of pelvic sarcomas between 2013 and 2023 at the National Center for Oncological Hadrontherapy, Pavia, Italy. Clinical outcomes, toxicity, and cumulative doses were analyzed.

Results

The median prescribed total dose of CIR was 60 GyRBE (range, 45-73.6 GyRBE). The maximum cumulative equivalent dose in 2 Gy fractions to the target volume reached 284 Gy, with a median of 153 Gy. The median follow-up was 32.5 months. The 1-, 2-, and 3-year locoregional progression-free survival rates were 79.1%, 43.9%, and 25.1%, respectively, with a mean time to locoregional relapse of 18.9 months. The 1-, 2-, and 3-year overall survival rates were 100%, 93.9%, and 83.1%, respectively. At last follow-up, grade 3 neuropathy occurred in 6.5% of the patients, grade 3 anorectal dysfunction in 8.7%, and grade 3 skin toxicity in 6.5%.

Conclusions

High-dose CIR is a feasible salvage strategy for recurrent pelvic sarcoma, offering promising outcomes and manageable toxicity in carefully selected patients. Prospective studies are warranted to refine dose-response models and validate long-term efficacy.

Autor:innen und Institutionen

  • Radiation Oncology Unit, Clinical Department, CNAO National Center for Oncological Hadrontherapy, Pavia, Italy.
  • Radiation Oncology Unit, Physics Department, CNAO National Center for Oncological Hadrontherapy, Pavia, Italy.
  • Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy.
  • Clinical Department, CNAO National Center for Oncological Hadrontherapy, Pavia, Italy.
  • Department of Clinical, Surgical, Diagnostic, and Pediatric Sciences, University of Pavia, Pavia, Italy.

Zitieren

APA

Chalaszczyk, A., Ferrari, E. D., Rotondi, M., Molinelli, S., Barcellini, A., Vitolo, V., Fontana, G., Scardo, S., Magro, G., Bazani, A., Ciocca, M., Orlandi, E., & Fiore, M. R. (2026). High-Dose Carbon Ion Reirradiation for Recurrent Pelvic Sarcomas: A Retrospective Analysis of Oncologic Outcomes in a Referral Center. Advances in Radiation Oncology, 11(11), 102137. https://doi.org/10.1016/j.adro.2026.102137

Vancouver

Chalaszczyk A, Ferrari ED, Rotondi M, Molinelli S, Barcellini A, Vitolo V, et al. High-Dose Carbon Ion Reirradiation for Recurrent Pelvic Sarcomas: A Retrospective Analysis of Oncologic Outcomes in a Referral Center. Advances in Radiation Oncology. 2026;11(11):102137. doi:10.1016/j.adro.2026.102137

BibTeX
@article{Chalaszczyk2026,
  author = {Chalaszczyk, Agnieszka and Ferrari, Elettra Dorotea and Rotondi, Marco and Molinelli, Silvia and Barcellini, Amelia and Vitolo, Viviana and Fontana, Giulia and Scardo, Sara and Magro, Giuseppe and Bazani, Alessia and Ciocca, Mario and Orlandi, Ester and Fiore, Maria Rosaria},
  title = {High-Dose Carbon Ion Reirradiation for Recurrent Pelvic Sarcomas: A Retrospective Analysis of Oncologic Outcomes in a Referral Center},
  journal = {Advances in Radiation Oncology},
  year = {2026},
  volume = {11},
  number = {11},
  pages = {102137},
  doi = {10.1016/j.adro.2026.102137}
}
Kostenlos starten →